Skip NavigationSkip to Content

Predicting tumor cell line response to drug pairs with deep learning

  1. Author:
    Xia, Fangfang
    Shukla, Maulik
    Brettin, Thomas
    Garcia-Cardona, Cristina
    Cohn, Judith
    Allen, Jonathan E.
    Maslov, Sergei
    Holbeck, Susan L.
    Doroshow, Jim
    Evrard, Yvonne
    Stahlberg, Eric
    Stevens, Rick L.
  2. Author Address

    Argonne Natl Lab, Comp Environm & Life Sci, Lemont, IL USA.Univ Chicago, Computat Inst, Chicago, IL 60637 USA.Los Alamos Natl Lab, Ctr Nonlinear Studies, Los Alamos, NM USA.Los Alamos Natl Lab, Comp Sci, Los Alamos, NM USA.Lawrence Livermore Natl Lab, Computat Directorate, Livermore, CA USA.Univ Illinois, Dept Bioengn, Urbana, IL USA.Univ Illinois, Carl R Woese Inst Genom Biol, Urbana, IL USA.NCI, Dev Therapeut Branch, Frederick, MD 21701 USA.Frederick Natl Lab Canc Res, Data Sci & Informat Technol Program, Frederick, MD USA.
    1. Year: 2018
    2. Date: Dec 21
    3. Epub Date: 2018 12 21
  1. Journal: BMC bioinformatics
  2. BMC,
    1. 19
    2. Supp 18
  3. Type of Article: Article
  4. Article Number: 486
  5. ISSN: 1471-2105
  1. Abstract:

    BackgroundThe National Cancer Institute drug pair screening effort against 60 well-characterized human tumor cell lines (NCI-60) presents an unprecedented resource for modeling combinational drug activity.ResultsWe present a computational model for predicting cell line response to a subset of drug pairs in the NCI-ALMANAC database. Based on residual neural networks for encoding features as well as predicting tumor growth, our model explains 94% of the response variance. While our best result is achieved with a combination of molecular feature types (gene expression, microRNA and proteome), we show that most of the predictive power comes from drug descriptors. To further demonstrate value in detecting anticancer therapy, we rank the drug pairs for each cell line based on model predicted combination effect and recover 80% of the top pairs with enhanced activity.ConclusionsWe present promising results in applying deep learning to predicting combinational drug response. Our feature analysis indicates screening data involving more cell lines are needed for the models to make better use of molecular features.

    See More

External Sources

  1. DOI: 10.1186/s12859-018-2509-3
  2. PMID: 30577754
  3. WOS: 000454210600008

Library Notes

  1. Fiscal Year: FY2018-2019
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel